Reyon Pharmaceutical Co Ltd (102460) - Cash Flow Conversion Efficiency

Latest as of September 2025: -0.007x

Based on the latest financial reports, Reyon Pharmaceutical Co Ltd (102460) has a cash flow conversion efficiency ratio of -0.007x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-1.73 Billion ≈ $-1.17 Million USD) by net assets (₩233.12 Billion ≈ $157.98 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Reyon Pharmaceutical Co Ltd market cap and net worth for the company's overall valuation and market capitalisation.

Reyon Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2008–2024)

This chart illustrates how Reyon Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Reyon Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Reyon Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency. Explore 102460 cash flow quality score to measure how well operating cash flow supports reported net income.

Company	Cash Flow Conversion Efficiency
Etga Group Ltd TA:ETGA	-0.498x
Spring Valley Acquisition Corp. II Class A Ordinary Shares NASDAQ:SVII	-0.031x
Teladan Setia Group Bhd KLSE:0230	0.033x
Shimmick Corporation Common Stock NASDAQ:SHIM	-0.011x
ABL Group ASA OL:ABL	0.040x
Wam Research Ltd AU:WAX	0.017x
Black Mammoth Metals Corp V:BMM	-0.010x
Quanterix Corp NASDAQ:QTRX	0.011x

Annual Cash Flow Conversion Efficiency for Reyon Pharmaceutical Co Ltd (2008–2024)

The table below shows the annual cash flow conversion efficiency of Reyon Pharmaceutical Co Ltd from 2008 to 2024. View Reyon Pharmaceutical Co Ltd stock quote for real-time trading data and today's change.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2024-12-31	₩249.94 Billion ≈ $169.38 Million	₩-1.44 Billion ≈ $-973.03K	-0.006x	-116.52%
2023-12-31	₩248.62 Billion ≈ $168.49 Million	₩8.65 Billion ≈ $5.86 Million	0.035x	-1.31%
2022-12-31	₩247.77 Billion ≈ $167.91 Million	₩8.73 Billion ≈ $5.92 Million	0.035x	-26.06%
2021-12-31	₩245.24 Billion ≈ $166.19 Million	₩11.68 Billion ≈ $7.92 Million	0.048x	+138.35%
2020-12-31	₩230.09 Billion ≈ $155.93 Million	₩4.60 Billion ≈ $3.12 Million	0.020x	+136.47%
2019-12-31	₩222.29 Billion ≈ $150.64 Million	₩-12.18 Billion ≈ $-8.26 Million	-0.055x	-207.90%
2018-12-31	₩225.39 Billion ≈ $152.74 Million	₩11.45 Billion ≈ $7.76 Million	0.051x	-33.44%
2017-12-31	₩219.66 Billion ≈ $148.86 Million	₩16.76 Billion ≈ $11.36 Million	0.076x	+44.31%
2016-12-31	₩179.10 Billion ≈ $121.37 Million	₩9.47 Billion ≈ $6.42 Million	0.053x	-72.89%
2012-12-31	₩126.36 Billion ≈ $85.63 Million	₩24.65 Billion ≈ $16.70 Million	0.195x	+34.09%
2011-12-31	₩105.47 Billion ≈ $71.48 Million	₩15.34 Billion ≈ $10.40 Million	0.145x	+0.12%
2009-12-31	₩59.76 Billion ≈ $40.50 Million	₩8.68 Billion ≈ $5.88 Million	0.145x	+3.49%
2008-12-31	₩42.63 Billion ≈ $28.89 Million	₩5.99 Billion ≈ $4.06 Million	0.140x	--

About Reyon Pharmaceutical Co Ltd

KO:102460 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$125.41 Million

₩185.06 Billion KRW

Market Cap Rank

#18432 Global

#826 in Korea

Share Price

₩10090.00

Change (1 day)

+0.20%

52-Week Range

₩9770.00 - ₩12570.00

All Time High

₩70413.22